Relationship between platelet/hemoglobin and radial thrombus in patients with coronary angiography via radial access.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Biomarkers in medicine Pub Date : 2024-01-10 DOI:10.2217/bmm-2023-0394

Sidar Ş Aydın, Emrah Aksakal, İbrahim Saraç, Faruk Aydınyılmaz, Murat Özmen, Oktay Gülcü, Selim Aydemir, Kamuran Kalkan

引用次数: 0

Abstract

Aim: To predict the development of radial artery thrombus (RAT) in patients with radial approach coronary angiography of platelet-to-hemoglobin ratio (PHR). Materials & methods: This study was designed to evaluate the relationship between RAT and PHR. A total of 1156 patients who had coronary angiography via the transradial approach between 2021 and 2022 in the authors' center were included in the study. Results: Radial thrombus was detected in 52 (4.5%) patients. PHR was higher in the group with thrombus and was statistically significant. In the regression model, PHR was an independent predictor of the development of radial thrombus (p = 0.007). Conclusion: High PHR may be an independent predictor of the development of radial thrombus.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

经桡动脉入路进行冠状动脉造影术患者的血小板/血红蛋白与桡动脉血栓之间的关系。

目的：通过血小板血红蛋白比值（PHR）预测桡动脉入路冠状动脉造影患者桡动脉血栓（RAT）的发生。材料和方法：本研究旨在评估 RAT 与 PHR 之间的关系。研究纳入了作者所在中心 2021 年至 2022 年期间通过经桡动脉途径进行冠状动脉造影的 1156 例患者。研究结果52例（4.5%）患者检测到桡动脉血栓。有血栓组的 PHR 较高，且有统计学意义。在回归模型中，PHR 是桡动脉血栓形成的独立预测因子（P = 0.007）。结论高 PHR 可能是桡动脉血栓形成的独立预测因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.